Inhibition of IKKε and TBK1 improves glucose control in a subset of patients with type 2 diabetes
Numerous studies indicate an inflammatory link between obesity and type 2 diabetes. The inflammatory kinases IKKε and TBK1 are elevated in obesity; their inhibition in obese mice reduces weight, insulin resistance, fatty liver and inflammation. Here we studied amlexanox, an inhibitor of IKKε/TBK1, i...
Gespeichert in:
Veröffentlicht in: | Cell metabolism 2017-07, Vol.26 (1), p.157-170.e7 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 170.e7 |
---|---|
container_issue | 1 |
container_start_page | 157 |
container_title | Cell metabolism |
container_volume | 26 |
creator | Oral, Elif A. Reilly, Shannon M. Gomez, Andrew V. Meral, Rasimcan Butz, Laura Ajluni, Nevin Chenevert, Thomas L. Korytnaya, Evgenia Neidert, Adam Hench, Rita Rus, Diana Horowitz, Jeff Poirier, BreAnne Zhao, Peng Lehmann, Kim Jain, Mohit Yu, Ruth Liddle, Christopher Ahmadian, Maryam Downes, Michael Evans, Ronald M. Saltiel, Alan R. |
description | Numerous studies indicate an inflammatory link between obesity and type 2 diabetes. The inflammatory kinases IKKε and TBK1 are elevated in obesity; their inhibition in obese mice reduces weight, insulin resistance, fatty liver and inflammation. Here we studied amlexanox, an inhibitor of IKKε/TBK1, in a proof-of-concept randomized, double blind, placebo-controlled study of 42 obese patients with type 2 diabetes and nonalcoholic fatty liver disease. Treatment of patients with amlexanox produced a statistically significant reduction in Hemoglobin A1c and fructosamine. Interestingly, a subset of drug responders also exhibited improvements in insulin sensitivity and hepatic steatosis. This subgroup was characterized by a distinct inflammatory gene expression signature from biopsied subcutaneous fat at baseline. They also exhibited a unique pattern of gene expression changes in response to amlexanox, consistent with increased energy expenditure. Together, these data suggest that IKKε/TBK1 inhibitors may be effective therapies for metabolic disease in an identifiable subset of patients.
XXX et al investigate the effect of the anti-inflammatory/antiallergic drug amlexanox in a proof-of-concept clinical study of type 2 diabetes and nonalcoholic fatty liver disease. Amlexanox improved blood glucose levels in diabetic patients and a sub-group showed enhanced response, including liver fat loss, associated with increased energy expenditure. |
doi_str_mv | 10.1016/j.cmet.2017.06.006 |
format | Article |
fullrecord | <record><control><sourceid>pubmedcentral</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5663294</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_5663294</sourcerecordid><originalsourceid>FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_56632943</originalsourceid><addsrcrecordid>eNqljEtOwzAURS0EooV2A4zeBmL8SdxkwgAEosq088hJ3OZViW3ZTlEXxjZYE0ViwpjRPdLRuYQ8cEY54-rxSLvJJCoY31CmKGPqiix5JUW2yQW7vnBRsCznki_IXYxHxqSSlbwlC1GqUopSLkm7tQO2mNBZcHvY1vXXJ2jbw-655oCTD-5kIhzGuXPRQOdsCm4EtKAhzm006SfzOqGxKcIHpgHS2RsQ0KNuTTJxRW72eoxm_bv35Ontdffynvm5nUzfXcKgx8YHnHQ4N05j89dYHJqDOzWFUlJUufz3wTcUcmWO</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Inhibition of IKKε and TBK1 improves glucose control in a subset of patients with type 2 diabetes</title><source>Cell Press Free Archives</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Access via ScienceDirect (Elsevier)</source><creator>Oral, Elif A. ; Reilly, Shannon M. ; Gomez, Andrew V. ; Meral, Rasimcan ; Butz, Laura ; Ajluni, Nevin ; Chenevert, Thomas L. ; Korytnaya, Evgenia ; Neidert, Adam ; Hench, Rita ; Rus, Diana ; Horowitz, Jeff ; Poirier, BreAnne ; Zhao, Peng ; Lehmann, Kim ; Jain, Mohit ; Yu, Ruth ; Liddle, Christopher ; Ahmadian, Maryam ; Downes, Michael ; Evans, Ronald M. ; Saltiel, Alan R.</creator><creatorcontrib>Oral, Elif A. ; Reilly, Shannon M. ; Gomez, Andrew V. ; Meral, Rasimcan ; Butz, Laura ; Ajluni, Nevin ; Chenevert, Thomas L. ; Korytnaya, Evgenia ; Neidert, Adam ; Hench, Rita ; Rus, Diana ; Horowitz, Jeff ; Poirier, BreAnne ; Zhao, Peng ; Lehmann, Kim ; Jain, Mohit ; Yu, Ruth ; Liddle, Christopher ; Ahmadian, Maryam ; Downes, Michael ; Evans, Ronald M. ; Saltiel, Alan R.</creatorcontrib><description>Numerous studies indicate an inflammatory link between obesity and type 2 diabetes. The inflammatory kinases IKKε and TBK1 are elevated in obesity; their inhibition in obese mice reduces weight, insulin resistance, fatty liver and inflammation. Here we studied amlexanox, an inhibitor of IKKε/TBK1, in a proof-of-concept randomized, double blind, placebo-controlled study of 42 obese patients with type 2 diabetes and nonalcoholic fatty liver disease. Treatment of patients with amlexanox produced a statistically significant reduction in Hemoglobin A1c and fructosamine. Interestingly, a subset of drug responders also exhibited improvements in insulin sensitivity and hepatic steatosis. This subgroup was characterized by a distinct inflammatory gene expression signature from biopsied subcutaneous fat at baseline. They also exhibited a unique pattern of gene expression changes in response to amlexanox, consistent with increased energy expenditure. Together, these data suggest that IKKε/TBK1 inhibitors may be effective therapies for metabolic disease in an identifiable subset of patients.
XXX et al investigate the effect of the anti-inflammatory/antiallergic drug amlexanox in a proof-of-concept clinical study of type 2 diabetes and nonalcoholic fatty liver disease. Amlexanox improved blood glucose levels in diabetic patients and a sub-group showed enhanced response, including liver fat loss, associated with increased energy expenditure.</description><identifier>ISSN: 1550-4131</identifier><identifier>EISSN: 1932-7420</identifier><identifier>DOI: 10.1016/j.cmet.2017.06.006</identifier><identifier>PMID: 28683283</identifier><language>eng</language><ispartof>Cell metabolism, 2017-07, Vol.26 (1), p.157-170.e7</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids></links><search><creatorcontrib>Oral, Elif A.</creatorcontrib><creatorcontrib>Reilly, Shannon M.</creatorcontrib><creatorcontrib>Gomez, Andrew V.</creatorcontrib><creatorcontrib>Meral, Rasimcan</creatorcontrib><creatorcontrib>Butz, Laura</creatorcontrib><creatorcontrib>Ajluni, Nevin</creatorcontrib><creatorcontrib>Chenevert, Thomas L.</creatorcontrib><creatorcontrib>Korytnaya, Evgenia</creatorcontrib><creatorcontrib>Neidert, Adam</creatorcontrib><creatorcontrib>Hench, Rita</creatorcontrib><creatorcontrib>Rus, Diana</creatorcontrib><creatorcontrib>Horowitz, Jeff</creatorcontrib><creatorcontrib>Poirier, BreAnne</creatorcontrib><creatorcontrib>Zhao, Peng</creatorcontrib><creatorcontrib>Lehmann, Kim</creatorcontrib><creatorcontrib>Jain, Mohit</creatorcontrib><creatorcontrib>Yu, Ruth</creatorcontrib><creatorcontrib>Liddle, Christopher</creatorcontrib><creatorcontrib>Ahmadian, Maryam</creatorcontrib><creatorcontrib>Downes, Michael</creatorcontrib><creatorcontrib>Evans, Ronald M.</creatorcontrib><creatorcontrib>Saltiel, Alan R.</creatorcontrib><title>Inhibition of IKKε and TBK1 improves glucose control in a subset of patients with type 2 diabetes</title><title>Cell metabolism</title><description>Numerous studies indicate an inflammatory link between obesity and type 2 diabetes. The inflammatory kinases IKKε and TBK1 are elevated in obesity; their inhibition in obese mice reduces weight, insulin resistance, fatty liver and inflammation. Here we studied amlexanox, an inhibitor of IKKε/TBK1, in a proof-of-concept randomized, double blind, placebo-controlled study of 42 obese patients with type 2 diabetes and nonalcoholic fatty liver disease. Treatment of patients with amlexanox produced a statistically significant reduction in Hemoglobin A1c and fructosamine. Interestingly, a subset of drug responders also exhibited improvements in insulin sensitivity and hepatic steatosis. This subgroup was characterized by a distinct inflammatory gene expression signature from biopsied subcutaneous fat at baseline. They also exhibited a unique pattern of gene expression changes in response to amlexanox, consistent with increased energy expenditure. Together, these data suggest that IKKε/TBK1 inhibitors may be effective therapies for metabolic disease in an identifiable subset of patients.
XXX et al investigate the effect of the anti-inflammatory/antiallergic drug amlexanox in a proof-of-concept clinical study of type 2 diabetes and nonalcoholic fatty liver disease. Amlexanox improved blood glucose levels in diabetic patients and a sub-group showed enhanced response, including liver fat loss, associated with increased energy expenditure.</description><issn>1550-4131</issn><issn>1932-7420</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNqljEtOwzAURS0EooV2A4zeBmL8SdxkwgAEosq088hJ3OZViW3ZTlEXxjZYE0ViwpjRPdLRuYQ8cEY54-rxSLvJJCoY31CmKGPqiix5JUW2yQW7vnBRsCznki_IXYxHxqSSlbwlC1GqUopSLkm7tQO2mNBZcHvY1vXXJ2jbw-655oCTD-5kIhzGuXPRQOdsCm4EtKAhzm006SfzOqGxKcIHpgHS2RsQ0KNuTTJxRW72eoxm_bv35Ontdffynvm5nUzfXcKgx8YHnHQ4N05j89dYHJqDOzWFUlJUufz3wTcUcmWO</recordid><startdate>20170705</startdate><enddate>20170705</enddate><creator>Oral, Elif A.</creator><creator>Reilly, Shannon M.</creator><creator>Gomez, Andrew V.</creator><creator>Meral, Rasimcan</creator><creator>Butz, Laura</creator><creator>Ajluni, Nevin</creator><creator>Chenevert, Thomas L.</creator><creator>Korytnaya, Evgenia</creator><creator>Neidert, Adam</creator><creator>Hench, Rita</creator><creator>Rus, Diana</creator><creator>Horowitz, Jeff</creator><creator>Poirier, BreAnne</creator><creator>Zhao, Peng</creator><creator>Lehmann, Kim</creator><creator>Jain, Mohit</creator><creator>Yu, Ruth</creator><creator>Liddle, Christopher</creator><creator>Ahmadian, Maryam</creator><creator>Downes, Michael</creator><creator>Evans, Ronald M.</creator><creator>Saltiel, Alan R.</creator><scope>5PM</scope></search><sort><creationdate>20170705</creationdate><title>Inhibition of IKKε and TBK1 improves glucose control in a subset of patients with type 2 diabetes</title><author>Oral, Elif A. ; Reilly, Shannon M. ; Gomez, Andrew V. ; Meral, Rasimcan ; Butz, Laura ; Ajluni, Nevin ; Chenevert, Thomas L. ; Korytnaya, Evgenia ; Neidert, Adam ; Hench, Rita ; Rus, Diana ; Horowitz, Jeff ; Poirier, BreAnne ; Zhao, Peng ; Lehmann, Kim ; Jain, Mohit ; Yu, Ruth ; Liddle, Christopher ; Ahmadian, Maryam ; Downes, Michael ; Evans, Ronald M. ; Saltiel, Alan R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_56632943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oral, Elif A.</creatorcontrib><creatorcontrib>Reilly, Shannon M.</creatorcontrib><creatorcontrib>Gomez, Andrew V.</creatorcontrib><creatorcontrib>Meral, Rasimcan</creatorcontrib><creatorcontrib>Butz, Laura</creatorcontrib><creatorcontrib>Ajluni, Nevin</creatorcontrib><creatorcontrib>Chenevert, Thomas L.</creatorcontrib><creatorcontrib>Korytnaya, Evgenia</creatorcontrib><creatorcontrib>Neidert, Adam</creatorcontrib><creatorcontrib>Hench, Rita</creatorcontrib><creatorcontrib>Rus, Diana</creatorcontrib><creatorcontrib>Horowitz, Jeff</creatorcontrib><creatorcontrib>Poirier, BreAnne</creatorcontrib><creatorcontrib>Zhao, Peng</creatorcontrib><creatorcontrib>Lehmann, Kim</creatorcontrib><creatorcontrib>Jain, Mohit</creatorcontrib><creatorcontrib>Yu, Ruth</creatorcontrib><creatorcontrib>Liddle, Christopher</creatorcontrib><creatorcontrib>Ahmadian, Maryam</creatorcontrib><creatorcontrib>Downes, Michael</creatorcontrib><creatorcontrib>Evans, Ronald M.</creatorcontrib><creatorcontrib>Saltiel, Alan R.</creatorcontrib><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cell metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oral, Elif A.</au><au>Reilly, Shannon M.</au><au>Gomez, Andrew V.</au><au>Meral, Rasimcan</au><au>Butz, Laura</au><au>Ajluni, Nevin</au><au>Chenevert, Thomas L.</au><au>Korytnaya, Evgenia</au><au>Neidert, Adam</au><au>Hench, Rita</au><au>Rus, Diana</au><au>Horowitz, Jeff</au><au>Poirier, BreAnne</au><au>Zhao, Peng</au><au>Lehmann, Kim</au><au>Jain, Mohit</au><au>Yu, Ruth</au><au>Liddle, Christopher</au><au>Ahmadian, Maryam</au><au>Downes, Michael</au><au>Evans, Ronald M.</au><au>Saltiel, Alan R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibition of IKKε and TBK1 improves glucose control in a subset of patients with type 2 diabetes</atitle><jtitle>Cell metabolism</jtitle><date>2017-07-05</date><risdate>2017</risdate><volume>26</volume><issue>1</issue><spage>157</spage><epage>170.e7</epage><pages>157-170.e7</pages><issn>1550-4131</issn><eissn>1932-7420</eissn><abstract>Numerous studies indicate an inflammatory link between obesity and type 2 diabetes. The inflammatory kinases IKKε and TBK1 are elevated in obesity; their inhibition in obese mice reduces weight, insulin resistance, fatty liver and inflammation. Here we studied amlexanox, an inhibitor of IKKε/TBK1, in a proof-of-concept randomized, double blind, placebo-controlled study of 42 obese patients with type 2 diabetes and nonalcoholic fatty liver disease. Treatment of patients with amlexanox produced a statistically significant reduction in Hemoglobin A1c and fructosamine. Interestingly, a subset of drug responders also exhibited improvements in insulin sensitivity and hepatic steatosis. This subgroup was characterized by a distinct inflammatory gene expression signature from biopsied subcutaneous fat at baseline. They also exhibited a unique pattern of gene expression changes in response to amlexanox, consistent with increased energy expenditure. Together, these data suggest that IKKε/TBK1 inhibitors may be effective therapies for metabolic disease in an identifiable subset of patients.
XXX et al investigate the effect of the anti-inflammatory/antiallergic drug amlexanox in a proof-of-concept clinical study of type 2 diabetes and nonalcoholic fatty liver disease. Amlexanox improved blood glucose levels in diabetic patients and a sub-group showed enhanced response, including liver fat loss, associated with increased energy expenditure.</abstract><pmid>28683283</pmid><doi>10.1016/j.cmet.2017.06.006</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1550-4131 |
ispartof | Cell metabolism, 2017-07, Vol.26 (1), p.157-170.e7 |
issn | 1550-4131 1932-7420 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5663294 |
source | Cell Press Free Archives; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Access via ScienceDirect (Elsevier) |
title | Inhibition of IKKε and TBK1 improves glucose control in a subset of patients with type 2 diabetes |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T15%3A32%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibition%20of%20IKK%CE%B5%20and%20TBK1%20improves%20glucose%20control%20in%20a%20subset%20of%20patients%20with%20type%202%20diabetes&rft.jtitle=Cell%20metabolism&rft.au=Oral,%20Elif%20A.&rft.date=2017-07-05&rft.volume=26&rft.issue=1&rft.spage=157&rft.epage=170.e7&rft.pages=157-170.e7&rft.issn=1550-4131&rft.eissn=1932-7420&rft_id=info:doi/10.1016/j.cmet.2017.06.006&rft_dat=%3Cpubmedcentral%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_5663294%3C/pubmedcentral%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/28683283&rfr_iscdi=true |